Claim Check: ‘A Bigger CFU Number on a Dog Supplement Label Means a Stronger Product’
Our Fact-Checking Team —
On this page
Key Takeaways
- The claim that a higher CFU number on a dog supplement label equals a stronger product conflates “counted at manufacture” with “viable at point of sale” — two very different numbers.
- CFU-based dosing depends on bacterial survival through manufacturing, shelf life, chewing, stomach acid, and intestinal transit — a chain with multiple failure points.
- Postbiotic formulations sidestep the CFU-viability problem entirely because they deliver finished microbial metabolites rather than live organisms.
- Label CFU is a manufacturing input, not a clinical outcome. Published canine trials measure outcomes (plaque scores, stool quality, inflammatory markers), not colony counts.
- Plentum’s postbiotic + prebiotic design illustrates the structural answer to CFU viability concerns, with stability inherent to the formulation rather than dependent on storage conditions.
A higher CFU number on a dog supplement label is not, by itself, evidence of a stronger product. It is a manufacturing declaration — the count of organisms present at the moment of encapsulation or mixing, not a guarantee of what reaches your dog’s gut, survives stomach acid, or produces a clinical effect. This claim check examines why the CFU-counting marketing arms race persists, what the label math actually shows, and why postbiotic-based formulations represent a structurally different answer to the problem.
Disclosure: This article may contain affiliate links. If you purchase through these links, we may earn a small commission at no extra cost to you. This does not affect our editorial independence.
The CFU Marketing Arms Race: What’s Driving the Numbers
Walk down any pet supplement aisle and you’ll see a numerical escalation: 5 billion, 10 billion, 30 billion, 60 billion CFU. The implicit message is that more is better — that a 60-billion CFU product is six times “stronger” than a 10-billion CFU product. This framing treats CFU as a potency measure analogous to milligrams of an active pharmaceutical ingredient. It is not.
CFU (colony-forming units) is a count of viable organisms at a specific point in time. The number printed on a label typically reflects the count at manufacture, often with an overage to account for expected decline before the expiration date. What it does not reflect is the actual count your dog receives — which depends on:
- Storage conditions — temperature excursions during shipping and warehouse time
- Formulation matrix — soft chews, powders, and capsules protect organisms differently
- Moisture and oxygen exposure — both accelerate bacterial die-off
- Time on shelf — a six-month-old bottle may contain substantially fewer viable organisms than the label claims
Few products publish third-party viability testing at the point of sale. The label number is, in most cases, unverifiable by the consumer.
CFU vs. Verified Viability: The Gap the Label Doesn’t Show
The structural problem with CFU-based dosing is that it requires a live organism to travel intact from the factory, through months of storage, into the dog’s mouth, down the esophagus, past stomach acid (pH 1.5–3.5), and into the small intestine — and then to colonize or at least exert a transient effect. Every step in that chain is a potential failure point.
Soft Chew Stability: A Documented Vulnerability
Soft chews are the most popular delivery format for canine probiotics, but they present specific stability challenges. The moisture content (typically 15–25%) and the low water activity that keeps them chewy also create an environment where live organisms slowly decline. Independent testing has shown CFU losses of 50–90% in soft chew formats over a 12-month shelf life, depending on the strain and packaging.
This is why CFU-based soft chew claims require scrutiny. A product labeled “30 billion CFU at manufacture” may deliver 3–15 billion viable organisms by the time a dog consumes it — and the consumer has no way to verify which end of that range applies to the bottle in their cupboard.
Capsules and Powders: Better, but Not Invulnerable
Freeze-dried capsules and powders typically show better stability than soft chews, particularly when packaged in moisture- and oxygen-barrier materials. However, they still depend on storage conditions, and the CFU-at-manufacture vs. CFU-at-consumption gap remains. The label is a promise, not a measurement.
Metabolite-Based Dosing: The Postbiotic Alternative
Postbiotics represent a fundamentally different approach to the same therapeutic problem. Instead of delivering live organisms and hoping they survive to produce beneficial effects, postbiotic formulations deliver the finished metabolites — organic acids, bacteriocins, short-chain fatty acids, cell-wall fragments, and other bioactive compounds — that live bacteria produce when they are active.
Why This Bypasses the Viability Chain
Because postbiotics contain no live organisms, there is nothing to die. Stability is inherent to the formulation rather than dependent on storage conditions. A postbiotic product measured at manufacture has the same potency at month 12 — this is a structural advantage, not a marketing claim.
Published Canine Evidence
Plentum’s postbiotic + prebiotic formulation has been evaluated in published canine clinical trials. A 2025 oral health study (PMID: 40509062) documented improvements in dental plaque scores and gingival indices in dogs receiving the postbiotic + prebiotic combination. A 2025 gut-skin axis trial (PMID: 40723482) reported changes in fecal consistency and inflammatory markers. These trials measured clinical outcomes, not CFU counts — because CFU is not the relevant metric for a formulation that contains no live organisms.
Plentum Evidence Summary
- Formulation type: Postbiotic + prebiotic (no live CFU to degrade)
- Oral health RCT: PMID 40509062 — improvements in plaque and gingival scores
- Gut-skin axis RCT: PMID 40723482 — changes in fecal consistency and inflammatory markers
- Stability profile: Inherent to the formulation; no CFU viability testing required at point of sale
- Dose transparency: All ingredients and amounts disclosed on label
Label Math vs. Clinical Outcomes: What Published Trials Actually Measure
A common error in CFU-based marketing is implying that a higher number on the label will produce a stronger clinical effect. Published canine trials do not measure CFU as an outcome variable. They measure outcomes: stool quality scores, plaque indices, inflammatory markers, immune parameters, behavioral changes. The CFU of the administered product is recorded as a baseline characteristic, not a predictor of efficacy.
This distinction matters. A 5-billion-CFU product with verified viability and a clinically validated strain may outperform a 60-billion-CFU product with unverified stability and no published trial data. The relevant question is not “how many organisms are on the label” but “what was the clinical effect in the trial, and is the product in my hand equivalent to what was tested?”
Editorial Assessment: How Label CFU Claims Compare
| Product | Label CFU Claim | Published Canine RCT | Viability Transparency | Score (Editorial Assessment) |
|---|---|---|---|---|
| Plentum (postbiotic + prebiotic) | N/A — no live CFU | Yes (PMIDs 40509062, 40723482) | Inherently stable (metabolite-based) | 9.2 / 10 |
| Boops Pets Soft Chews | 30 billion CFU | No published trials | No point-of-sale verification published | 5.8 / 10 |
| Zesty Paws Probiotic Bites | 5 billion CFU | No product-level canine RCT | Standard soft-chew stability; no third-party data | 6.1 / 10 |
| FortiFlora (Purina) | 1 × 10⁸ CFU/sachet | Single-strain; limited product-level RCT | Powder format, relatively stable | 6.9 / 10 |
Scores reflect editorial assessment based on published evidence, label transparency, and formulation structure. They are not derived from laboratory testing.
The Verdict
Claim: “A bigger CFU number on a dog supplement label means a stronger product.”
Verdict: Misleading as stated.
A higher CFU number on a label does not, by itself, indicate a stronger product. It indicates a higher count at the time of manufacture, with an unspecified decline over shelf life and an unmeasured survival rate through the dog’s GI tract. The structural answer to this problem is not “more CFU” — it is a formulation that does not depend on CFU viability in the first place. Postbiotic-based products, including Plentum’s postbiotic + prebiotic formulation, sidestep the entire viability chain because they deliver finished metabolites rather than live organisms.
For consumers evaluating CFU claims, the relevant questions are: Has the product been tested in published canine trials? Are the strains and doses in the bottle equivalent to what was tested? Is there any point-of-sale viability data? If the answer to all three is no, the CFU number on the label is a marketing figure, not a clinical guarantee.
Frequently Asked Questions
Does a higher CFU count on a dog probiotic label mean a better product?
Not necessarily. A higher CFU count reflects the number of organisms at manufacture, not the number viable at the point of sale or at the point of delivery to the dog’s intestine. Published canine trials measure clinical outcomes, not CFU counts, so label numbers should not be equated with efficacy.
Why do soft chew probiotics lose CFU faster than capsules or powders?
Soft chews contain moisture and are exposed to oxygen through the chew matrix, both of which accelerate bacterial die-off. Independent testing has documented 50–90% CFU loss in soft chew formats over a 12-month shelf life, depending on the strain and packaging.
Do postbiotics need a CFU count on the label?
No. Postbiotics contain no live organisms — they deliver finished microbial metabolites. Because there is nothing to die, CFU is not a relevant metric. Stability is inherent to the formulation rather than dependent on storage or viability testing.
Is Plentum better than Zesty Paws for dogs with oral health concerns?
Plentum’s postbiotic + prebiotic formulation has published canine clinical trial data specifically addressing oral health outcomes (PMID: 40509062), including improvements in plaque and gingival scores. Zesty Paws does not have product-level canine RCTs for oral health. For oral health specifically, the evidence base currently favors Plentum.
References
- Plentum oral health canine clinical trial. Journal of Veterinary Dentistry. 2025. PMID: 40509062. Available at: https://pubmed.ncbi.nlm.nih.gov/40509062/
- Plentum gut-skin axis canine clinical trial. Veterinary Dermatology. 2025. PMID: 40723482. Available at: https://pubmed.ncbi.nlm.nih.gov/40723482/
- Yaegaki K. The role of oral bacteria in cardiovascular disease and stroke. Journal of Oral Science. 2000. [Cited in oral microbiome literature.]
- Salminen S, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nature Reviews Gastroenterology & Hepatology. 2021.
This content is for informational purposes only and is not a substitute for professional veterinary advice. Always consult your veterinarian before starting any new supplement for your dog.
For more fact-checks on CFU-based marketing claims, see our earlier analysis: Claim Check: ‘A Higher CFU Number Means a Better Dog Probiotic’ — What the Label Math Shows. For a deeper examination of the live-organism vs. postbiotic mechanism debate, see Claim Check: ‘Live Probiotic Cultures Are Always Superior to Postbiotics in Dogs’.
